Hims & Hers Health Inc. (HIMS) saw its stock soar 6.94% on Monday, following the company's announcement of key leadership appointments aimed at strengthening its focus on quality, safety, and regulatory compliance.
The telehealth firm appointed Deb Autor, a former deputy commissioner at the U.S. Food and Drug Administration (FDA), to its board of directors. Autor brings over 30 years of experience in pharmaceutical quality, compliance, regulatory programs, and consumer protection. During her tenure at the FDA, she oversaw inspections, criminal investigations, and international operations for the agency.
Additionally, Hims & Hers named Janet Stevens as its Global Head of Quality & Safety. Stevens has spent her entire career in pharmaceutical quality assurance, operations, and engineering. She previously served as the Chief Quality Officer at Hillrom, where she helped the company achieve top-quartile results in global quality regulations.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.